Genetic medicines are paving the way for groundbreaking treatments in cardiovascular diseases (CVD). With advancements in gene therapy, RNA-based therapies, stem cell research, and gene editing, a growing number of clinical trials are underway.

This meeting will bring together diverse groups of basic scientists, clinicians, and industry professionals to foster meaningful discussions of the exciting opportunities emerging from industry-academia collaborations/partnerships. The sessions will explore cutting-edge advancements in identifying new therapeutic targets, translational research and clinical studies aimed at treating CVD. Topics will include breakthroughs in genetic therapies, as well as challenges related to delivery methods, efficacy, safety and cardiac tissue modeling to better understand disease phenotypes.

Additionally, the program will feature panel discussions focused on the steps leading from basic discovery to translation, commercialization, FDA approval, and navigating the venture capital landscape. Other key topics will include long-term and off-target effects of therapies, ethical and regulatory considerations, lessons from preclinical and clinical trials, and professional development challenges for early-career researchers.

The meeting brings together basic researchers, clinicians and industry partners demonstrating the crucial role that interdisciplinary collaborations play in driving growth in this area.  The sessions will highlight not only the latest scientific discoveries and their translational impact but also explore key challenges. The program will delve into the requirements for pre-clinical and clinical trial design, offering insights into research strategies, particularly in emerging areas like gene therapies, and the integration of AI in therapeutics advancements.